

APPLICATION FOR THE REGISTRATION OF A TRADE MARK  
Sections 9, 14, 16, 42, 43 and 63 - Regulations 11, 56 and 57

APPLICATION FOR REGISTRATION OF THE ACCOMPANYING TRADE  
MARK IS HEREBY MADE BY THE UNDERMENTIONED APPLICANT

For office use only

21	Application Number	
22	Filing Date	

Applicant's or agent's reference	TA3308940/CEW
GPA number	1185/2000

NA	Nature (O=Ordinary, CE=Certification, CO=Collective, CU=Honest Concurrent User)	O	
73	Applicant	74	Address for service
Gilead Sciences, Inc., a corporation organised and existing under the laws of the State of Delaware, 333 Lakeside Drive, Foster City, California 94404, United States of America		Spoor & Fisher, 11 Byls Bridge Boulevard, Building No. 14, Highveld Ext 73, Centurion, Pretoria (P O Box 454, PRETORIA, 0001, South Africa) DOCEX 61 PRETORIA	

57	Specification of goods/services	51	International Classification	44
----	---------------------------------	----	------------------------------	----

Medical services, namely, providing information regarding the prevention of HIV infection.

58	Endorsement(s)
See Annexure	

Convention priority claimed	31	Number	32	Date	33	Country
		87227314		4 November 2016		United States of America

54	Representation of trade mark	AS	Association No. (if applicable)
----	------------------------------	----	---------------------------------



The applicant claims to be the proprietor of the accompanying trade mark which is proposed to be or is being used in respect of the aforementioned specification of goods / services.

Date: See official date receipt stamp

.....  
Signature of applicant or authorised agent

**PRIORITY DOCUMENTS TO FOLLOW**

25 April 2017

## **SCHEDULE**

58: Endorsement(s) - Annexure:

Registration of this trade mark shall give no right to the exclusive use of "emtricitabine 200 mg", "tenofovir disoproxil fumarate 300 mg tablets", "for" or "pre-exposure prophylaxis", separately and apart from the mark.

The combination of the colours blue and orange, as depicted on the representation accompanying the application, is an essential and distinctive feature of the mark.

The mark consists of a diamond shape having a blue top and an orange bottom, divided by a wavy band that is the color of the background along with the word TRUVADA to the right and the words emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg tablets beneath TRUVADA. The bottom of the mark consists of a blue oblong shaped pill design with a capital letter P, lower case r, capital letter E and capital letter P within the pill design. The word "for" is to the left of the blue pill design and the words "pre-exposure prophylaxis" are to the right of the blue pill design, as depicted in this application.

The trade mark TRUVADA has no known meaning and is an invented word.

**TRUVADA for PrEP**